Director Declaration
In brief · summary, not quotable
No summary for this filing – the full text is below.
Full announcement
Select text to share a quote on X · sign in to keep highlights & notes in your OXB notes
Oxford, UK - 9 August 2024: Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica" or "the Company"), a quality and innovation-led cell and gene therapy CDMO, today announces that Heather Preston, Non-Executive Director, has been appointed as Non-Executive Director of Aligos Therapeutics, a Nasdaq listed company, effective 7 August 2024.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.